Onsg-082 Review

SUBJECT: ONSG-082

Lira’s voice trembled. “They’re… they’re not human.” Onsg-082

• The core patent covers the allosteric pocket and a family of cyclic peptides (including Onsg‑082). However, competitors could design non‑peptidic small molecules targeting the same site. The next few years could see a flurry of patents and potential litigation.

When the first whispers of Onsg‑082 appeared in a pre‑print from the University of Zurich last summer, the scientific community responded with the typical mix of intrigue and healthy skepticism. A tiny, synthetically‑derived peptide, Onsg‑082 was presented as a “next‑generation, allosteric modulator” for the NOD‑like receptor family—the cellular sentinels that orchestrate inflammation, immunity, and tissue repair. Fast forward nine months, and that modest peptide has already entered Phase I/II clinical trials for three distinct indications: autoimmune arthritis, fibrotic lung disease, and rare metabolic neuropathy. SUBJECT: ONSG-082 Lira’s voice trembled